Iodine Deficiency: Goitre, Cretinism, and the Silent Threat to Brain Development

In communities of the Democratic Republic of Congo where endemic iodine deficiency has persisted for generations, neurological cretinism - characterised by profound intellectual disability, deaf-mutism, and spastic diplegia - affects up to 10% of the population in the most severely affected inland villages. Even among children who appear clinically normal in these same communities, intelligence quotient (IQ) scores measured in controlled studies run 10–15 points below those of iodine-replete comparison populations ( Zimmermann, 2009 ). That invisible IQ deficit, unaccompanied by any visible neck swelling or recognisable syndrome, is the central paradox of iodine deficiency disorders (IDD): the most consequential damage occurs precisely where it cannot be seen.

Globally, an estimated two billion people live in areas of insufficient iodine intake, making IDD the world’s most common preventable cause of brain damage and the leading preventable cause of intellectual disability ( Zimmermann et al., 2008 ). Sub-Saharan Africa carries a disproportionate share of this burden, and while universal salt iodisation has transformed the landscape in many regions, fragmented supply chains, weak regulatory enforcement, and the perennial challenge of reaching remote highland populations mean that deficiency persists where its consequences are most devastating.

This article maps the full spectrum of iodine deficiency disorders - from palpable goitre and overt cretinism to the subtler, population-level cognitive losses that receive far less policy attention than they deserve - and examines the epidemiological evidence, the biology of iodine in foetal brain development, and the public health architecture that has been built to address these disorders over the past four decades.

The Spectrum of Iodine Deficiency Disorders

The term “iodine deficiency disorders” was introduced by Basil Hetzel in a landmark 1983 Lancet paper to convey that the clinical consequences of iodine deficiency extend well beyond the enlarged thyroid gland that lay audiences recognise as goitre (Hetzel BS, 1983, Lancet, 2:1126–1129). Hetzel’s framing was epidemiologically important: it shifted the focus from a single visible sign to a spectrum of functional and developmental consequences that collectively represent an enormous, largely preventable burden of ill-health.

Goitre: Grades and Pathophysiology

When dietary iodine is insufficient, the thyroid gland - which concentrates iodine from the circulation to synthesise the hormones thyroxine (T₄) and triiodothyronine (T₃) - responds by increasing in size in an attempt to extract more iodine from a depleted blood pool. This compensatory hypertrophy produces goitre, the most visible manifestation of IDD.

The WHO/ICCIDD/UNICEF grading system classifies goitre by palpation and, where available, ultrasound:

• Grade 0: No palpable or visible goitre.
• Grade 1: A goitre that is palpable but not visible when the neck is in the normal position. The thyroid moves upward in the neck when the subject swallows.
• Grade 2: A swelling in the neck that is clearly visible when the neck is in a normal position and is consistent with an enlarged thyroid on palpation.

In severe endemic areas, thyroid volumes measured by ultrasound may exceed normal reference values many times over; nodular transformation and autonomous function within the gland can develop with prolonged stimulation, occasionally resulting in thyrotoxicosis when iodine is abruptly replenished - a recognised complication of rapid salt iodisation programmes that requires monitoring.

Population-level goitre prevalence surveys remain the most widely used indicator of IDD burden at the community level, though they measure a chronic structural consequence rather than current iodine intake. For this reason, urinary iodine concentration (UIC) has become the preferred functional indicator in contemporary surveillance (see Monitoring, below).

Hypothyroidism and Its Consequences

Beyond goitre, sustained iodine deficiency leads to hypothyroidism - insufficient production of thyroid hormones with downstream effects on virtually every organ system. In adults, overt hypothyroidism produces the classical features of myxoedema: cold intolerance, weight gain, bradycardia, constipation, dry skin, and slowed cognition. Subclinical hypothyroidism - elevated thyroid-stimulating hormone (TSH) with normal free T₄ - is more prevalent and produces less dramatic but measurable effects on cognition, mood, and cardiovascular function.

In pregnancy, maternal hypothyroidism poses particular dangers because the developing foetus depends entirely on maternal thyroid hormone supply during the first trimester, before the foetal thyroid has become functional. Even modest reductions in maternal free T₄ during early gestation have been associated with measurable cognitive and neuromotor deficits in offspring - a finding that has profound implications for populations in whom subclinical deficiency during pregnancy is prevalent ( Vanderpump et al., 2011 ).

Cretinism: The Most Severe Expression

Endemic cretinism is the most extreme consequence of severe iodine deficiency during foetal development. Two distinct phenotypes are recognised, though overlap is common:

Neurological cretinism - the predominant form in most endemic regions of Africa and Asia - is characterised by severe intellectual disability, deaf-mutism, and motor deficits including spastic diplegia or quadriplegia. It arises from maternal iodine deficiency during the first and second trimesters, when thyroid hormone is critical for neuronal proliferation, migration, and myelination in the developing brain. The brain damage is irreversible; correction of iodine status after birth does not restore neurological function once these critical windows have passed.

Myxoedematous cretinism - more characteristic of the DRC and some other African highland regions - presents with profound hypothyroidism, severe growth retardation, and intellectual disability, but without the deafness and neuromotor spasticity of the neurological form. Its pathophysiology is less completely understood but involves both severe iodine deficiency and, in some settings, concurrent selenium deficiency, which impairs the metabolism of thyroid hormones.

The global prevalence of cretinism in high-deficiency regions before salt iodisation programmes reached scale was estimated in the millions; large-scale supplementation and iodisation have reduced incident cretinism dramatically, but cases continue to occur in areas where coverage of iodised salt or supplementation is incomplete ( Pearce et al., 2013 ).

The Critical and Often Overlooked Problem: Subclinical Deficiency and IQ Loss

The fraction of the global IDD burden that is most consequential in absolute terms is the least visible: the population-wide cognitive deficit produced by mild-to-moderate iodine deficiency, in which no individual meets criteria for cretinism and no neck swelling is present. This is the silent injury that Hetzel’s framing sought to make legible, and it remains underappreciated in public health discourse.

Meta-analyses consistently document that children raised in iodine-deficient areas score an average of 10–15 IQ points below those in iodine-sufficient areas, after controlling for confounders ( Zimmermann, 2009 ). At a population level, a 10-point downward shift in the IQ distribution is an enormous burden: it roughly doubles the proportion of individuals with IQ below 70 (the clinical threshold for intellectual disability), while simultaneously truncating the upper end of cognitive performance that drives educational attainment and economic productivity. Bhutta and colleagues, in their landmark 2013 Lancet analysis of nutrition-sensitive interventions, estimated that micronutrient deficiencies including iodine deficiency collectively account for a substantial portion of the global burden of developmental disability in low- and middle-income countries ( Bhutta et al., 2013 ).

The mechanism operates primarily through thyroid hormone’s role in neuronal differentiation, dendritic branching, synaptogenesis, and myelination of white matter tracts during foetal and neonatal life. Thyroid hormone receptors are expressed widely in the developing brain from around 10 weeks of gestation, and animal experiments demonstrate that even transient hypothyroxinaemia during defined developmental windows produces permanent architectural abnormalities in hippocampal and cortical circuits.

Crucially, the brain injury from subclinical maternal iodine deficiency is not accompanied by clinical goitre in the mother, nor by any visible abnormality in the infant. Standard clinical examination is blind to it. The only way to detect the problem at a population level is through systematic biochemical surveillance of iodine status in vulnerable groups - principally pregnant women and school-age children - and through assessment of thyroid function markers including TSH and free T₄.

The UK iodine status survey published by Vanderpump and colleagues offers a cautionary example from a high-income setting: a national survey of schoolgirls found that 51% were iodine-deficient by urinary iodine concentration criteria - a finding that prompted serious concern about intergenerational cognitive consequences in a country that had previously assumed adequate status ( Vanderpump et al., 2011 ). If mild iodine deficiency persists undetected in a high-income country with functional health surveillance, the problem in under-monitored low-income settings is likely to be substantially more severe and more invisible.

Global Burden and Epidemiology

The most widely cited estimate places approximately two billion people at risk of iodine deficiency worldwide, with the burden concentrated in South Asia, Sub-Saharan Africa, parts of the former Soviet Union, and mountain populations of Latin America - regions characterised by iodine-poor soils from which dietary iodine is naturally scarce ( Zimmermann et al., 2008 ).

A comprehensive 2012 global status update using data from 149 countries found that 29.8% of the global school-age population had insufficient iodine intake (UIC < 100 µg/L), with the highest prevalences in the WHO African and European regions ( Andersson et al., 2012 ). Progress has been substantial - in 1990, an estimated 110 countries were iodine-deficient; by the early 2010s this had fallen to around 32 - but the pace of improvement has been uneven, and some countries have stalled or reversed.

The Iodine Global Network (IGN) annual scorecard tracks national iodine nutrition status using a classification scheme based on median UIC in school-age children: deficient (< 100 µg/L), adequate (100–299 µg/L), more than adequate (300–499 µg/L), or excessive (≥ 500 µg/L). The 2021 IGN scorecard found that 21 countries remained iodine-deficient, of which a disproportionate number were in Sub-Saharan Africa and South Asia (IGN, 2021). Equally, the scorecard documented emerging problems at the other extreme: over-iodination from poorly controlled fortification programmes in a small number of countries, though this remains a less widespread concern than under-iodination.

Sub-Saharan Africa: Patterns and Heterogeneity

Within Sub-Saharan Africa, iodine status is heterogeneous and does not map neatly onto income or development indicators. Landlocked, highland, and inland riverine populations are at greatest structural risk because their dietary iodine derives entirely from locally produced foods grown on iodine-poor soils, without the marine dietary sources that protect coastal communities. The Great Lakes region of East Africa - encompassing parts of Uganda, Tanzania, Rwanda, Burundi, and the DRC - has historically been among the most severely iodine-deficient areas in the world.

National household surveys and nutrition assessments have documented persistent moderate deficiency in several Sahelian countries despite years of nominal salt iodisation policies. Reasons include inconsistent iodisation at salt production or import points, degradation of potassium iodate during storage in hot, humid conditions, the dominance of unregulated small-scale salt sources that bypass formal quality control, and limited institutional capacity for monitoring and enforcement. In some countries, the formal salt iodisation regulation exists on paper while the majority of households consume non-iodised salt purchased from informal markets.

A review of data from multiple African countries confirms the persistent gap between policy and household-level reality: median UIC surveys in school-age children in several West African nations have documented values well below the 100 µg/L adequacy threshold despite years of nominal iodisation programmes in place ( Andersson et al., 2012 ). Pregnant women - the most vulnerable subgroup - are rarely the primary target of UIC surveillance, meaning that the subpopulation at greatest risk of transmitting iodine deficiency to the next generation is precisely the one about which least is known.

Iodine in Foetal Brain Development: The Biological Basis of the Risk

Understanding why iodine deficiency during pregnancy is so consequential requires attention to the developmental biology of thyroid hormone action in the brain. The foetal thyroid gland becomes capable of autonomous hormone synthesis only from around 18–20 weeks of gestation. Before this point, the foetus is entirely dependent on maternal thyroid hormones transported across the placenta. Even after foetal thyroid function is established, the foetus continues to rely heavily on maternal T₄ as a precursor for the intracellular generation of T₃ in the developing brain.

Thyroid hormones regulate the expression of genes involved in neuronal proliferation in the ventricular zone, radial migration of neurons to the cortical plate, axonal outgrowth, synapse formation, and the synthesis of myelin by oligodendrocytes. The specificity and irreversibility of the damage produced by thyroid hormone deficiency during defined developmental windows reflects the fact that these processes follow a strict temporal programme: if the hormonal signal is absent during the critical window, the resulting structural disorganisation cannot be remedied by later hormone replacement.

The period of highest vulnerability is the first and second trimesters, particularly the neuronal proliferation phase between 8 and 16 weeks. Animal studies using thyroidectomised rodent models demonstrate that even a two-to-three week window of hypothyroxinaemia during this phase produces permanent hippocampal disorganisation, reduced cortical neuron number, and impaired spatial learning - changes that persist even when euthyroidism is restored immediately afterward.

In women who enter pregnancy with marginal iodine status, the substantial additional iodine demand of pregnancy - driven by increased thyroid hormone production, foetal iodine uptake, and renal iodine losses - pushes them into frank deficiency. WHO recommends an iodine intake of 250 µg/day for pregnant and lactating women, compared with 150 µg/day for non-pregnant adults. Meeting this target through diet alone is difficult in iodine-poor regions; it requires either adequate iodised salt consumption or targeted supplementation with iodine-containing prenatal micronutrients.

Salt Iodisation: The Architecture of a Global Intervention

The global response to IDD is built primarily on universal salt iodisation (USI) - the addition of potassium iodate (or, less commonly, potassium iodide) to all salt intended for human and animal consumption at a standard concentration sufficient to meet population iodine requirements. Salt was chosen as the vehicle because it is consumed in relatively consistent quantities across socioeconomic groups, is produced at a small number of centralised facilities amenable to quality control, and is inexpensive to fortify.

The institutional framework for USI was largely shaped by the International Council for Control of Iodine Deficiency Disorders (ICCIDD, now the Iodine Global Network), WHO, and UNICEF, whose 1993 joint statement on USI set international targets. The WHO/UNICEF/ICCIDD recommended iodine level in salt is 20–40 mg potassium iodate per kilogram at the point of production, calibrated to deliver approximately 150–250 µg iodine per person per day assuming typical salt consumption of 5–10 g/day.

The scale of the achievement since 1990 is remarkable. The proportion of households globally consuming adequately iodised salt rose from approximately 10% in 1990 to over 70% by the mid-2010s, and the number of iodine-deficient countries fell correspondingly ( Pearce et al., 2013 ). In countries where USI has been implemented with high coverage - including multiple East and Southern African nations - goitre prevalence has declined dramatically, the incidence of cretinism has fallen to near-zero, and population UIC surveys have moved into the adequate range.

Limitations of the Salt Iodisation Model

Despite these gains, the USI model faces structural limitations that bear directly on the persistence of IDD in Sub-Saharan Africa.

Informal salt supply chains are the dominant challenge. Where salt production or importation is distributed across many small-scale operators, ensuring that all production is iodised to the required standard is technically and administratively demanding. In several West African countries, the majority of salt consumed in rural areas passes through informal channels that are not subject to iodisation requirements or quality control testing.

Salt iodine losses during storage and cooking can be substantial. Potassium iodate is relatively stable, but exposure to heat, light, and moisture accelerates degradation; household salt stored in open containers in tropical conditions may retain only a fraction of its initial iodine content by the time it is consumed. The use of salt in cooking - particularly prolonged boiling in open pots - also reduces iodine content.

Declining salt consumption in populations where processed food intake is low - but particularly in populations following public health advice to reduce sodium intake - can result in iodine intakes falling below requirements even when salt is adequately iodised. This tension between sodium reduction advice and iodine sufficiency is increasingly recognised in high-income-country public health discourse and is beginning to be relevant in middle-income African contexts as well.

Pregnant women’s additional requirements cannot reliably be met through iodised salt alone where household iodised salt coverage is imperfect. WHO recommends that pregnant and lactating women in regions where USI is not yet achieving adequate coverage should receive supplemental iodine; the evidence base for this recommendation was reviewed comprehensively by Bhutta and colleagues in their 2013 Lancet series on nutrition-specific interventions, which concluded that iodine supplementation in deficient pregnant women produces meaningful improvements in child cognitive outcomes ( Bhutta et al., 2013 ).

The broader architecture of micronutrient intervention programming is explored in the site’s analysis of the role of micronutrient interventions in global health , which contextualises iodisation within the wider landscape of fortification, supplementation, and dietary diversification strategies.

Monitoring Iodine Status: Urinary Iodine Concentration and Beyond

Because more than 90% of ingested iodine is excreted in urine, urinary iodine concentration (UIC) provides a direct measure of recent dietary iodine intake and is the primary biomarker for assessing population iodine status. UIC is typically measured in spot urine samples and expressed as micrograms per litre (µg/L); the median UIC in a population sample reflects community-level adequacy rather than individual status, since UIC varies substantially from day to day within individuals.

WHO criteria classify population iodine status as follows:

The higher UIC target for pregnant women reflects the substantially elevated iodine requirements of gestation. National surveys typically use school-age children (6–12 years) as the sentinel population - they are accessible through school-based sampling and their UIC correlates reasonably well with community-level iodine availability - but this group is not the most biologically vulnerable. Surveys of pregnant women require dedicated sampling effort and remain under-resourced in most low-income settings, creating a persistent data gap at the critical biological interface.

Complementary indicators for IDD surveillance include thyroid volume by ultrasound (assessing chronic structural effect), serum thyroglobulin (a sensitive marker of thyroid function that rises with both iodine deficiency and excess), and neonatal TSH from dried blood spot screening. The combination of UIC and thyroglobulin is increasingly recommended for comprehensive surveillance because the two biomarkers respond on different time scales - UIC reflects days-to-weeks dietary intake, while thyroglobulin reflects months of iodine status - providing richer information than either alone.

Population-level data systems capable of tracking these indicators longitudinally are discussed in the site’s overview of comparative approaches to food security monitoring , which addresses the infrastructure requirements for sustaining meaningful nutrition surveillance across diverse settings.

Sub-Saharan Africa: Country-Level Evidence

Data from national nutrition surveys across Sub-Saharan Africa reveal the uneven progress of iodisation and the persistence of pockets of severe deficiency.

Ethiopia, whose highland regions include some of the most iodine-poor soils on the continent, has made substantial progress since the introduction of mandatory salt iodisation in the early 2010s, but household iodised salt coverage surveys continue to document significant rural-urban disparities. National surveys have found median UIC values in the adequate range for urban school-age children but deficient values in highland rural areas, where community access to iodised salt depends on extended informal supply chains.

Nigeria, the most populous country in the region, has a complex iodine landscape: coastal populations obtain some iodine from seafood and marine-derived salt, while inland populations are considerably more vulnerable. A national micronutrient survey found that while household iodised salt coverage had improved considerably, substantial sub-national heterogeneity persisted, with northern states showing the lowest coverage and the highest goitre prevalences (IGN, 2021).

The Democratic Republic of Congo remains among the most severely iodine-deficient countries globally, with large proportions of the population consuming non-iodised salt from informal local production. Neurological cretinism remains clinically evident in isolated highland communities, and population surveys document median UIC values well below the adequacy threshold in multiple provinces ( Pearce et al., 2013 ).

Tanzania and Uganda have achieved substantially higher household iodised salt coverage - in some surveys exceeding 80% - and have correspondingly documented improvements in population UIC and reductions in goitre prevalence, illustrating what consistent regulatory enforcement combined with investment in salt iodisation infrastructure can achieve.

These country examples underscore that progress is achievable but not automatic; it requires sustained institutional commitment, quality assurance throughout the salt supply chain, and monitoring systems capable of identifying the populations left behind.

Limitations and Methodological Considerations

Several important methodological limitations constrain the current evidence base on IDD burden and programme impact, and should be acknowledged when interpreting the data presented in this review.

Spot urine UIC as a population indicator performs well for assessing aggregate population status but is poorly suited for classifying individual status or for detecting within-individual variation. Day-to-day variation in iodine excretion is substantial - a coefficient of variation of 30–40% is typical - and a single spot urine measurement provides only a rough approximation of habitual intake. Multiple samples per individual, or 24-hour urine collections, provide more reliable individual-level data but are impractical in large surveys.

The exclusive reliance on school-age children as the sentinel population for national UIC surveys systematically underrepresents the most biologically vulnerable subgroups: pregnant women, infants, and pre-school-age children. Survey estimates of national iodine adequacy based on school-age children may therefore overstate the true protection of the most vulnerable groups, particularly in settings where dietary patterns differ between age groups.

Goitre surveys, while still widely reported, reflect the chronic cumulative structural effect of past iodine deficiency and are poorly responsive to recent changes in iodine status. A population whose iodine intake has improved over the preceding one to two years may still show elevated goitre prevalence because goitre regression is slow - making goitre an unsuitable real-time indicator of programme impact.

Cognitive outcome studies face the inherent challenge of establishing causation in observational settings where iodine deficiency is often correlated with poverty, low educational attainment of caregivers, food insecurity, and other developmental risk factors. Randomised controlled trials of iodine supplementation with cognitive outcomes as primary endpoints are methodologically challenging to conduct and ethically constrained in populations where deficiency is known to be harmful. The existing randomised evidence, predominantly from iodine supplementation trials in school-age children, shows consistent positive effects on cognitive measures but with confidence intervals that are wider than desirable, partly due to small sample sizes ( Zimmermann, 2009 ).

Iodine losses during salt storage and cooking are inconsistently measured across studies, meaning that household salt iodisation coverage data - often derived from salt titration on a sample of household salt at one point in time - may overestimate effective dietary iodine delivery.

Interaction with selenium and other micronutrients is biologically important but inadequately characterised in field settings. Selenium is required for the enzymatic conversion of T₄ to the more biologically active T₃, and for the selenoprotein glutathione peroxidase, which protects the thyroid from hydrogen peroxide-mediated oxidative damage generated during thyroid hormone synthesis. Co-deficiency of selenium and iodine, documented in parts of Central Africa, may modify the clinical phenotype of IDD and the response to iodine repletion, but the operational implications have not been fully translated into surveillance or intervention design.

Frequently Asked Questions

What is the difference between iodine deficiency goitre and goitre caused by other conditions?

Goitre - an enlarged thyroid gland - can arise from several causes, of which iodine deficiency is globally the most common but not the only one. Autoimmune thyroid disease (including Hashimoto’s thyroiditis and Graves’ disease), thyroid nodules, and thyroid carcinoma can all produce thyroid enlargement. Endemic iodine deficiency goitre is distinguished by its geographical clustering in iodine-poor regions, its high population prevalence, the absence of positive thyroid autoantibodies on testing, and its responsiveness - at least in early stages - to correction of iodine intake. In clinical practice in endemic areas, a palpable or visible goitre in a patient from an iodine-deficient region should be evaluated first for IDD but with autoimmune and neoplastic causes formally excluded, particularly where the goitre is rapidly enlarging, asymmetric, or accompanied by compressive symptoms.

What are the most common iodine deficiency symptoms in adults without clinical goitre?

The most frequently reported iodine deficiency symptoms in adults with subclinical or mild deficiency are non-specific: fatigue, cold intolerance, difficulty concentrating, and mild weight gain - all consistent with subclinical hypothyroidism. Many adults with mild deficiency are entirely asymptomatic on clinical examination, and the diagnosis is only made if thyroid function tests and UIC are measured. This clinical silence is precisely what makes subclinical deficiency so important from a public health perspective: the absence of obvious iodine deficiency symptoms does not preclude meaningful impairment of thyroid function or, in pregnancy, significant risk to foetal brain development.

Can iodine supplementation in pregnancy reverse or prevent cognitive deficits in the child?

The timing of intervention relative to the critical window of foetal brain development determines whether neurological damage is preventable. If adequate iodine status is established before conception and maintained throughout the first and second trimesters, the principal risk of neurological cretinism and subclinical cognitive impairment can be substantially reduced. Evidence from randomised trials in iodine-deficient populations indicates that iodine supplementation beginning before or in early pregnancy produces significantly better cognitive outcomes in offspring compared to supplementation beginning later in gestation or at birth. Supplementation begun only after delivery protects the infant from further postnatal deficiency but cannot reverse structural brain changes that occurred during foetal development. This irreversibility is the strongest possible argument for prioritising iodine status assessment and correction before and during early pregnancy ( Bhutta et al., 2013 ).

Why does iodine deficiency persist in Sub-Saharan Africa despite decades of salt iodisation programmes?

Persistence reflects the intersection of several structural challenges that are not resolved simply by enacting iodisation regulations. Informal salt supply chains - dominated by small-scale producers and traders operating outside formal quality control systems - account for the majority of salt consumed in many rural areas. Iodine degradation during storage in tropical conditions erodes the iodate content of formally iodised salt before it reaches the household. Regulatory enforcement capacity in food safety agencies is frequently inadequate. And iodisation policies have not consistently been accompanied by the monitoring infrastructure needed to detect populations that remain deficient. Furthermore, pregnant women - the group with the greatest need - are rarely the primary target of household iodised salt coverage surveys, which typically measure availability rather than adequacy in the most vulnerable subpopulation. Sustained progress requires enforcement, monitoring, and targeted supplementation programmes working in parallel, not sequential steps (IGN, 2021; Andersson et al., 2012 ).

References

Andersson, M., Karumbunathan, V., & Zimmermann, M.B. (2012). Global iodine status in 2011 and trends over the past decade. Journal of Nutrition, 142(4), 744–750. https://doi.org/10.1093/jn/nxr059

Bhutta, Z.A., Das, J.K., Rizvi, A., Gaffey, M.F., Walker, N., Horton, S., … Black, R.E. (2013). Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? The Lancet, 382(9890), 452–477. https://doi.org/10.1016/S0140-6736(13)60996-4

Hetzel, B.S. (1983). Iodine deficiency disorders (IDD) and their eradication. The Lancet, 2(8359), 1126–1129.

Iodine Global Network. (2021). Global Scorecard of Iodine Nutrition in 2021. IGN.

Pearce, E.N., Andersson, M., & Zimmermann, M.B. (2013). Global iodine nutrition: where do we stand in 2013? Thyroid, 23(5), 523–528. https://doi.org/10.1089/thy.2013.0609

Vanderpump, M.P.J., Lazarus, J.H., Smyth, P.P., Laurberg, P., Holder, R.L., Boelaert, K., & Franklyn, J.A. (2011). Iodine status of UK schoolgirls: a cross-sectional survey. The Lancet, 377(9782), 2007–2012. https://doi.org/10.1016/S0140-6736(11)60813-6

Zimmermann, M.B. (2009). Iodine deficiency. Endocrine Reviews, 30(4), 376–408; see also American Journal of Clinical Nutrition, 89(2), 668S–672S. https://doi.org/10.1093/ajcn/89.2.668S

Zimmermann, M.B., Jooste, P.L., & Pandav, C.S. (2008). Iodine-deficiency disorders. Lancet, 372(9645), 1251–1262. https://doi.org/10.1111/j.1467-3010.2008.00718.x